InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Freeman Mason, Directeur Exécutif du Développement Clinique. Insider active across 1 company, notably CinCor Pharma, Inc.. Aggregated, 3 disclosures have been published. Breakdown: 1 buy · 1 sell. Total volume traded: €35k. History available since 11 January 2022. The latest transaction was disclosed on 10 June 2022 (Cession). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Freeman Mason
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
6 shares@ US$15.210.1% of flowCommon StockSEC:0001209191-23-013268:0
40,000 sharesCommon StockSEC:0001209191-23-005588:0
2,500 shares@ US$16.0050.0% of flowCommon StockSEC:0001209191-22-003188:0
Canonical exit: 11 Apr 2022 (T+90)
3 of 3 declarations
About Freeman Mason
Mason Freeman is the EVP Clinical Development at CinCor Pharma, Inc. In this role, he oversees clinical development programs and ensures that clinical trials are conducted in compliance with regulatory standards. His expertise is essential for the success of the company's research initiatives.
